PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS

Massachusetts researcher explores how childhood trauma becomes "somatically encoded" in gut disorders

2025-06-03
(Press-News.org) BOSTON, Massachusetts, USA, 3 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Erin E. Mauney reveals how her pioneering research brings psychedelic medicine into gastroenterology for the first time, potentially transforming treatment for millions suffering from intractable irritable bowel syndrome (IBS).

The assistant professor of pediatrics at Tufts University, who maintains a research appointment at Massachusetts General Hospital, leads the first clinical trial examining psilocybin's effects on treatment-resistant IBS. Her work addresses a critical gap in medicine: the substantial population of IBS patients who find no relief through conventional therapies.

Breaking New Ground in Gut-Brain Medicine

Dr. Mauney's research explores how psilocybin modulates interoception – the way people perceive their body and gastrointestinal symptoms. The study protocol involves two doses of psilocybin with integrated therapy sessions before and after dosing, combined with neuroimaging via fMRI to track brain changes.

"I became very interested in the applicability of this emerging field of psychedelic-assisted medicine to patients who seem to be at war with their bodies," Dr. Mauney explains in the interview. Her approach recognizes that many patients with severe, unexplained somatic symptoms have experienced significant trauma, particularly in early life.

The research emerges from Dr. Mauney's observation that medicine, especially gastroenterology and obesity medicine, often fails to meaningfully understand and address the cumulative effects of toxic stress over the lifespan. This insight led her to investigate how early-life trauma becomes "somatically encoded" and how psychedelic therapy might create pathways for emotional release and functional improvement.

From Personal Curiosity to Professional Innovation

Dr. Mauney's journey into psychedelic research began during the pandemic when she read Michael Pollan's "How to Change Your Mind" while deciding to specialize in pediatric gastroenterology. Her background combines bacteriology research, including work on immune tolerance-inducing bacteria, with clinical expertise in integrative gastroenterology.

A setback that proved fortuitous occurred when Dr. Mauney wasn't accepted to her top fellowship choice at Boston Children's Hospital. Instead, she matched at Massachusetts General Hospital, where she gained access to mentors including Dr. Franklin King at the Center for the Neuroscience of Psychedelics and Dr. Brad Kuo at the Center for Neurointestinal Health – connections that would prove instrumental in launching her psychedelic research program.

Addressing the Mind-Body Divide

The study's significance extends beyond IBS treatment. Dr. Mauney hopes her work will help heal what she describes as "the schism between mind and body that so many physicians practice within." This artificial separation has long hindered effective treatment for functional gastrointestinal disorders, where psychological and physical symptoms intertwine.

Her research methodology combines quantitative measures – including patient-reported abdominal pain scores – with qualitative patient reflections and neuroimaging data. This multi-faceted approach aims to capture both the subjective experience of healing and objective biological changes. Could this integrated methodology become a model for studying other functional disorders where conventional treatments fall short?

Implications for Pediatric Medicine

While Dr. Mauney's current research focuses on adults, her pediatric background deeply informs her perspective. She notes that witnessing inequality and injustice daily in pediatrics, particularly regarding childhood obesity, motivates her broader vision for medicine. Her interest in pediatric obesity prevention requires what she calls "a full-scale realignment of our society's priorities," including food subsidies, urban design, educational approaches, and technology's impact on childhood.

This systemic thinking raises important questions: How might early intervention with trauma-informed approaches prevent the development of chronic functional disorders? What role could psychedelic therapy eventually play in addressing treatment-resistant conditions across the lifespan?

Personal Philosophy Shapes Scientific Approach

The interview reveals how Dr. Mauney's personal values influence her research approach. She emphasizes cultivating "honest, genuine relationships with each person you work with" and creating environments where people can bring their whole selves to work. Her motto, "We are what we repeatedly do," reflects her commitment to meticulous, persistent research that prioritizes patient wellbeing.

When asked about her greatest passion, Dr. Mauney responds: "Restoring humanity to the practice of medicine." This philosophy permeates her research design, which treats patients as whole persons rather than collections of symptoms. Her approach suggests a paradigm shift in how we conceptualize and treat functional disorders – moving from symptom suppression to addressing root causes, including psychological trauma.

Looking Forward: Scalable Solutions

Dr. Mauney's research aims not just to prove efficacy but to develop scalable therapeutic options. She envisions optimizing psychedelic therapy protocols to make them accessible in clinical settings, potentially offering hope to the millions of IBS patients worldwide who have exhausted conventional treatment options.

The timing of this research is particularly significant as psychedelic medicine gains mainstream acceptance. With multiple psychedelic compounds in late-stage clinical trials for various conditions, Dr. Mauney's work positions gastroenterology at the forefront of this therapeutic revolution. What other specialty areas might benefit from similar innovative approaches to treatment-resistant conditions?

Dr. Erin E. Mauney's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Psychedelics titled "Erin Mauney: Psychedelics as modulators of the gut-brain interaction," is freely available via Open Access on 3 June 2025 in Psychedelics at the following hyperlink: https://doi.org/10.61373/pp025k.0020.

About Psychedelics: Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671, online and 2997-268X, print) is a peer reviewed medical research journal published by Genomic Press, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society. Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/ Our full website is at: https://genomicpress.kglmeridian.com/

END


ELSE PRESS RELEASES FROM THIS DATE:

Renowned psychiatrist illuminates biological roots of mental illness through pioneering research

2025-06-03
MILANO, Italy, 3 June 2025 – In a comprehensive Genomic Press Interview published in Brain Medicine, Professor Francesco Benedetti shares his transformative journey from confronting childhood awareness of mental illness to becoming a leading figure in psychiatric research. As founder and leader of the Psychiatry & Clinical Psychobiology research unit at IRCCS Ospedale San Raffaele, Dr. Benedetti has dedicated decades to reclaiming psychiatry's rightful place within medical science. Professor ...

Ancient collagen can help identify a “wombat the size of a hippo” in the fossil record

2025-06-03
What happened to all the megafauna? From moas to mammoths, many large animals went extinct between 50 and 10,000 years ago. Learning why could provide crucial evidence about prehistoric ecosystems and help us understand future potential extinctions. But surviving fossils are often too fragmented to determine the original species, and DNA is not always recoverable, especially in hot or damp environments. Now scientists have isolated collagen peptide markers which allow them to identify three key megafauna ...

Being in nature can help people with chronic back pain manage their condition

2025-06-03
ing time in or around nature can provide people suffering from chronic lower back pain with a degree of escapism that helps them better manage their physical discomfort, a new study has shown. The research, published in The Journal of Pain, is the first of its kind to ask people experiencing chronic lower back pain – in some cases for almost 40 years – about the role nature plays in any coping strategies they employ to help manage their condition. The researchers found that people able to get out in nature said it enabled them to connect with ...

Eating rate has sustained effects on energy intake from ultra-processed diets, new study reveals

2025-06-03
Brussels, Belgium — 2 June 2025 — A randomized controlled trial (RCT) carried out by researchers from Wageningen University, the Netherlands, has provided new evidence that texture-derived differences in meal eating rate influence energy intake from diets composed of ultra-processed foods (UPFs). Over a 14-day period, participants consuming a UPF diet with textures that reduced their eating rate, had an average energy intake reduction of 369 kcal per day, compared to when they followed a 14-day UPF diet with textures that promoted a faster ...

Rise in expectant mothers in UK with autoimmune diseases since millennium

2025-06-02
Thousands more UK women who are having children have been diagnosed with an autoimmune condition now compared to the beginning of the millennium. In a paper published in Lancet Rheumatology today, researchers involved in the MuM-PreDiCT project run by the University of Birmingham and funded by the Medical Research Council have found that there has been increase by 4.7% in expectant mothers beginning pregnancy with autoimmune conditions. Analysis of electronic healthcare records (CPRD) taken from 2000-2021 found that there was a ...

Majority of riders and drivers in UK 'gig economy' suffer anxiety over ratings and pay, study suggests

2025-06-02
Some two-thirds of riders and drivers for food delivery and ride-hailing apps in the UK may work in fear of “unfair feedback” and experience anxiety over sudden changes to working hours, a new survey study led by the University of Cambridge suggests.* Three-quarters of riders and drivers in the study report anxiety over potential for income to drop, with over half (51%) saying they risk health and safety while working. Some 42% of delivery and driver gig workers say they suffer physical pain resulting from work. Riders ...

Virginia Tech researchers develop recyclable, healable electronics

2025-06-02
Between upgrades and breakdowns to cellphones, tablets, laptops, and appliances, so many electronics are getting tossed in the trash that they've taken on a name of their own: e-waste. According to a 2024 report issued by the United Nations, the amount of e-waste worldwide has almost doubled in the past 12 years, from 34 billion to 62 billion kilograms — the equivalent of 1.55 million shipping trucks — and it's estimated to hit 82 billion kilograms by 2030. Just 13.8 billion kilograms — about 20 percent of the total — is expected to be recycled, a number ...

Cognitive outcomes similar after noncardiac surgery whether perioperative hypotension- or hypertension-avoidance strategies employed

2025-06-02
Embargoed for release until 5:00 p.m. ET on Monday 2 June 2025    Follow @Annalsofim on X, Facebook, Instagram, threads, and Linkedin         Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.    ----------------------------       Cognitive ...

Research spotlight: regional disparities in opioid overdose mortality persist despite national decline

2025-06-02
Sarah Wakeman, MD, Senior Medical Director for Substance Use Disorder at Mass General Brigham, is the co-senior author and Will Oles, BS, of Harvard Medical School, is a corresponding author of a paper published in the Journal of General Internal Medicine, “Geographic Trends in Opioid and Polysubstance Overdose Deaths in the US, 2014-2023.”  Q: How would you summarize your study for a lay audience?  In May 2024, the Centers for Disease Control (CDC) announced a national decline in the ...

Fighting myeloma with fiber: Plant-based diet offers promise

2025-06-02
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.     Multiple myeloma is often preceded by early, non-cancerous conditions involving abnormal plasma cells, a type of white blood cell found in the bone marrow. Having a high body weight, ...

LAST 30 PRESS RELEASES:

Baby's microbiome may protect against childhood viral infection

Diabetes drug shows benefits for patients with liver disease

P2Y12 drugs may be better than aspirin to prevent heart attack and stroke in patients with coronary artery disease

Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

Landmark study reveals survival limits of kidney transplantation in older and high-risk patients

Targeting mitochondria to fight leukemia: Rice University-led research team pursues new treatment strategies

Antibiotics taken during pregnancy may reduce preterm births

Vigilance and targeted public health measures are essential in the face of the diphtheria epidemic that has affected vulnerable populations in Western Europe since 2022

New study: Personalized exercise boosts health for people with neuromuscular disease

FAMU-FSU College of Engineering researchers discover universal law of quantum vortex dynamics

AI analysis of ancient handwriting provides new age estimates for Dead Sea Scrolls

As many as 1 in 5 women with a history of pregnancy or testing for pregnancy report using crisis pregnancy centers across 4 US states

Six decades of data on North Atlantic phytoplankton reveal that their biomass has decreased up to 2% annually across most of the Atlantic Ocean, with potentially widespread implications for the wider

GPT-generated educational materials for urological cancer patients, translated by AI into five languages, are rated by doctors as easier to read than human-authored versions while being just as clear,

Ethical considerations for closing projects "well" in the context of withdrawal of USAID

How male mosquitoes target females—and avoid traps

Unlocking the timecode of the Dead Sea Scrolls

Heatwaves greatly influence parasite burden; likely spread of disease

Biggest boom since Big Bang: Hawaiʻi astronomers uncover most energetic explosions in universe

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage

Global team tracks unusual objects in Milky Way galaxy

Surgical ablation during CABG linked to improved survival in patients with preexisting atrial fibrillation, new study finds

New research finds specific learning strategies can enhance AI model effectiveness in hospitals

INRS and ELI deepen strategic partnership to train the next generation in laser science

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time

Scientists build first genetic "toggle switch" for plants, paving the way for smarter farming

Researchers unveil a groundbreaking clay-based solution to capture carbon dioxide and combat climate change

A game-changing way to treat stroke

Which mesh is best? Outcomes for abdominal ventral hernia repair patients projected by new research model

Novel truncated RNAs from jumping DNA encode reverse transcriptases in aging human brain

[Press-News.org] Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS
Massachusetts researcher explores how childhood trauma becomes "somatically encoded" in gut disorders